Västra Hamnen Corp. Finance

• Promising interim data in the phase I study
• Raised a net of MSEK 73 and received a loan commitment of MSEK 20
• Awaiting the final read-out, we keep our fair value at SEK 10.81 per share

In Lipum’s Q2 report, CEO Ola Sandborgh repeated that he expects to complete the phase I study with SOL-116 during the second half of 2024. Interim results indicate that the study will meet its primary safety and tolerability endpoints. The drug candidate has also shown expected and preferred pharmacokinetics. Currently, the last group including rheumatoid arthritis patients is about to be concluded.

We maintain our model assumptions until the phase I study is completed. Therefore, we keep our risk-adjusted fair value at SEK 10.81 per share for now. The full report is available here.